复发缓解型多发性硬化患者认知测试评分的纵向变化:DECIDE数据集分析
本研究利用DECIDE试验(1,814例复发缓解型多发性硬化患者)数据,描述长达144周随访中SDMT和PASAT评分的变化,并与T25FW比较。结果显示SDMT和PASAT评分持续改善(可能为练习效应),且改善事件多于恶化事件,而T25FW恶化事件逐渐增加;改变临床意义变化的定义或采用6个月确认可改变事件数但不改变整体行为。作者认为SDMT和PASAT不能准确反映RRMS患者的认知下降。
要点
- SDMT平均分从基线48.2(SD 16.1)升至144周52.6(SD 15.2),PASAT从47.0(SD 11.3)升至50.0(SD 10.8)。
- 随访期间SDMT和PASAT改善事件多于恶化事件,而T25FW恶化事件逐渐增加。
- 改变临床意义变化的定义或采用6个月确认可改变事件数但不影响整体行为。
核心结论
- SDMT和PASAT评分可能不能准确反映复发缓解型多发性硬化患者所经历的稳定认知下降。
- 这两个结局在基线后评分增加, complicating the interpretation of these outcome measures in clinical trials。
- 在推荐临床意义纵向变化的通用阈值之前,需要更多关于这些变化大小的研究。
研究设计与样本
- 使用DECIDE试验(clinicaltrials.gov标识NCT01064401)的数据集,该试验为大型随机对照复发缓解型多发性硬化试验。
- 描述长达144周随访中SDMT和PASAT的变化,并与计时25英尺步行(T25FW)的变化进行比较。
- DECIDE试验共纳入1,814例参与者。
主要发现
- SDMT平均分从基线48.2(SD 16.1)分升至144周52.6(SD 15.2)分,PASAT从基线47.0(SD 11.3)分升至144周50.0(SD 10.8)分。
- 评分改善最可能归因于练习效应。
- 整个试验期间,参与者SDMT和PASAT表现改善的可能性高于恶化,而T25FW恶化事件数逐渐增加。
- 改变SDMT和PASAT的临床意义变化定义或使用6个月确认可改变恶化或改善事件的总数,但不影响这些指标的整体行为。
关键数值与推荐
- SDMT的临床意义变化定义包括:任何变化、4分变化、8分变化和20%变化。
- PASAT的临床意义变化定义包括:任何变化、4分变化和20%变化。
- T25FW的临床意义变化定义为20%变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cognitive impairment is a common and impactful symptom of relapsing-remitting multiple sclerosis (RRMS). Cognitive outcome measures are often used in cross-sectional studies, but their performance as longitudinal outcome measures in clinical trials is not widely researched. In this study, we used data from a large clinical trial to describe change on the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) over up to 144 weeks of follow-up. METHODS: We used the data set from DECIDE (clinicaltrials.gov identifier NCT01064401), a large randomized controlled RRMS trial to describe change on the SDMT and PASAT over 144 weeks of follow-up. We compared change on these cognitive outcomes with change on the timed 25-foot walk (T25FW), a well-established physical outcome measure. We investigated several definitions for clinically meaningful change: any change, 4-point change, 8-point change, and 20% change for the SDMT, any change, 4-point change, and 20% change for the PASAT, and 20% change for the T25FW. RESULTS: DECIDE included 1,814 trial participants. SDMT and PASAT scores steadily improved throughout follow-up: the SDMT from a mean 48.2 (SD, 16.1) points at baseline to 52.6 (SD 15.2) at 144 weeks and the PASAT from 47.0 (SD 11.3) at baseline to 50.0 (SD 10.8) at 144 weeks. This improvement in scores is most likely due to a practice effect. Throughout the trial, participants were more likely to experience improvement than worsening of their SDMT and PASAT performance, whereas the number of worsening events on the T25FW steadily increased. Changing the definition of clinically meaningful change for the SDMT and PASAT or using a 6-month confirmation changed the overall number of worsening or improvement events but did not affect the overall behavior of these measures. DISCUSSION: Our findings suggest that the SDMT and PASAT scores do not accurately reflect the steady cognitive decline that people with RRMS experience. Both outcomes show postbaseline increases in scores, which complicates the interpretation of these outcome measures in clinical trials. More research into the size of these changes is needed before recommending a general threshold for clinically meaningful longitudinal change.
引用
- Castrogiovanni N, Mostert J, Repovic P, et al. Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset. Neurology. 2023. PMID: 37072219. doi:10.1212/WNL.0000000000207301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。